Neurocrine drops MS agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurocrine Biosciences discontinues NBI-5788 compound development for multiple sclerosis following the altered peptide ligand (APL) product's Phase II failure, the firm announces March 8. "The company will complete its other APL Phase II study, which is evaluating the APL technology for the treatment of type 1 diabetes, which is utilizing a different APL epitope," Neurocrine says. The Phase II MS trial failed to show statistical significance in 157 subjects over a nine-month period….
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.